908 related articles for article (PubMed ID: 30849513)
1. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
3. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
4. Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life.
Verso M; Agnelli G
Thromb Res; 2020 Jul; 191 Suppl 1():S123-S127. PubMed ID: 32736770
[TBL] [Abstract][Full Text] [Related]
5. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
6. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
7. [Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
Stebler-Fontaine L; Rossel A; Marti C; Righini M; Robert-Ebadi H
Rev Med Suisse; 2019 Dec; 15(674):2232-2235. PubMed ID: 31804034
[TBL] [Abstract][Full Text] [Related]
8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
Vedovati MC; Giustozzi M; Bonitta G; Agnelli G; Becattini C
Thromb Res; 2018 Oct; 170():175-180. PubMed ID: 30196195
[TBL] [Abstract][Full Text] [Related]
10. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Abdel-Razeq H; Finianos A; Taher AT
Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
Mulder FI; Bosch FTM; Young AM; Marshall A; McBane RD; Zemla TJ; Carrier M; Kamphuisen PW; Bossuyt PMM; Büller HR; Weitz JI; Middeldorp S; van Es N
Blood; 2020 Sep; 136(12):1433-1441. PubMed ID: 32396939
[TBL] [Abstract][Full Text] [Related]
15. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Sobieraj DM; Baker WL; Smith E; Sasiela K; Trexler SE; Kim O; Coleman CI
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):182S-187S. PubMed ID: 30244595
[TBL] [Abstract][Full Text] [Related]
18. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
20. Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?
Verso M; Franco L; Giustozzi M; Becattini C; Agnelli G
Thromb Res; 2018 Apr; 164 Suppl 1():S168-S171. PubMed ID: 29703477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
